Assay Prediction

Pathology

Clinical Features

Tissue of Origin

Veridex

Histology

IHC

Age/Sex

Sites of Metastasis

Response to Treatment

Survival (mo)

Sarcoma

Ovarian

PD carcinoma

vimentin+, NSE+, synaptophysin+,  CD117+, HMB45-, LCA-, chromogranin-,  actin-, desmin-, Pan CK-, EMA-, S100-

40/F

abdomen, pelvis, liver

PD

9

Sarcoma

Other

Adenocarcinoma

None

56/M

abdomen, liver

SD

24

Sarcoma

Other

PD carcinoma

CK7+, EMA+, CK20-, TTF1-, PLAP-

61/M

lung, lymph nodes

PD

12

Sarcoma

Other

PD carcinoma

AE1/AE3+, CK20+, NSE+, CK7-, CD30-, desmin-, synaptophysin-, EMA-

35/M

lung, liver, lymph nodes

PR

6

Sarcoma

Other

PD carcinoma

CK+, S100-, HMB45-

86/F

pericardial effusion, adrenal gland, liver

SD

5

Sarcoma

Unsuccessful

Adenocarcinoma

None

65/M

liver

SD

9

Table 6 : Clinicopathologic Characteristics of Patients with Sarcoma Predictions (n = 6)